Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Abstract Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) deve...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | inglés |
| Publicado: |
2020
|
| Acceso en línea: | https://doi.org/10.1038/s41389-020-00257-z https://www.nature.com/articles/s41389-020-00257-z.pdf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|